OncLive TV

Michael A. Postow, MD, discusses the significance of understanding how to identify late-onset irAEs and underlying comorbidities unrelated to treatment in melanoma.

Sara M. Tolaney, MD, MPH, discusses an analysis of depth of response in HER2-positive advanced/metastatic breast cancer treated with T-DXd plus pertuzumab.

Alessandra Tedeschi, MD, discusses data from a subgroup analysis of the phase 3 SEQUOIA trial in CLL/SLL.

Everett Meyer, MD, PhD, discusses the ongoing investigation of Orca-T with reduced-intensity conditioning in hematologic malignancies.

Toni Choueiri, MD, discusses the significance of the FDA approval of adjuvant belzutifan plus pembrolizumab in ccRCC.

Daniel H. Ahn, DO, discusses research surrounding the combination of atebimetinib and modified gemcitabine and nab-paclitaxel (Abraxane) in pancreatic cancer.

Talha Munir, MBChB, PhD, discusses the implications of an MAIC comparing zanubrutinib and ibrutinib in treatment-naive CLL.

Benjamin Croll, MD, discusses the present and potential future standing of biomarkers in RCC.

R. Lor Randall, MD, FACS, discusses how tumor-informed ctDNA sequencing can identify osteosarcoma relapse months before radiographic detection.

Mark D. Tyson, II, MD, MPH, discusses data from a real-world study of blue light cystoscopy in high-risk NMIBC.

Benjamin Croll, MD, discusses research focused on understanding response to systemic therapy in RCC.

Peter Voorhees, MD, discusses efficacy data for talquetamab plus daratumumab with or without pomalidomide from MonumenTAL-3.

Stephan Stilgenbauer, MD, discusses safety considerations for BGB-16673 and where its development is headed in chronic lymphocytic leukemia.

Branko Cuglievan, MD, discusses data for revumenib in the pediatric R/R KMT2AR-acute leukemias subgroup from AUGMENT-101.

Pavlos Msaouel, MD, PhD, discusses the rationale for examining panitumumab-based treatment in SMARCB1-deficient RMC.

Jennifer Marvin-Peek, MD, discusses data for azacitidine, venetoclax, and ivosidenib, in IDH1-mutated acute myeloid leukemia and their significance.

Vincent Picozzi, MD, discusses the FDA approval of Optune Pax for locally advanced pancreatic cancer and the criteria for optimal patient selection.

Mark D. Tyson, II, MD, MPH, discusses how TARA-002 could fit into the treatment landscape of BCG-naive NMIBC.

Jiong Wu, MD, PhD, discusses the significance of studying iza-bren in a phase 3 setting in unresectable, locally advanced or metastatic TNBC.

Glenn J. Hanna, MD, highlights interim efficacy and safety data from a phase 1 trial of Emi-Le in patients with aggressive adenoid cystic carcinoma.

Mark A. Socinski, MD, discusses data from stage 1 of the phase 3 PRESERVE-003 trial (NCT05671510) in patients with squamous NSCLC.

Marwan G. Fakih, MD, discusses how data from the POD1UM-303 trial support the use of retifanlimab in frontline squamous cell anal carcinoma.

Mark D. Tyson, II, MD, MPH, discusses efficacy data with TARA-002 in patients with BCG-naive high-grade non–muscle-invasive bladder cancer.

Daniel Olson, MD, discusses findings with brenetafusp from a phase 1/2 trial (NCT04262466) in patients with advanced melanoma.

Frederick Howard, MD, outlines limitations and opportunities for AI in breast pathology, shifting focus from workflow efficiency to prognostic value.

Elena Elimova, MD, discusses data from a HERIZON-GEA-01 PD-L1 subgroup analysis in HER2-positive gastroesophageal adenocarcinoma.

Matthew Galsky, MD, discusses the present and future use of biomarkers in bladder cancer.

Brad Haverkos, MD, discusses approaches for the management of mogamulizumab-associated rash in patients with cutaneous T-cell lymphoma.

Sonali M. Smith, MD, discusses implications of data for tafasitamab plus lenalidomide/R-CHOP in high-risk diffuse large B-cell lymphoma.

Cara A. Mathews, MD, discusses the updated findings from cohort D2 of the phase 1/2 RAINFOL-01 trial (NCT05579366) in advanced ovarian cancer.